Stephen B. Shrewsbury's most recent trade in Impel Pharmaceuticals Inc was a trade of 24,606 Common Stock done at an average price of $2.0 . Disclosure was reported to the exchange on March 29, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. | 29 Mar 2022 | 24,606 | 97,990 | - | 2.0 | 48,474 | Common Stock |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2022 | 24,606 | 0 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.95 per share. | 21 Sep 2021 | 53,954 | 73,384 | - | 2.9 | 159,164 | Common Stock |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 53,954 | 29,587 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. | 21 Sep 2021 | 14,780 | 14,780 | - | 2.0 | 29,117 | Common Stock |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 14,780 | 0 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. | 21 Sep 2021 | 4,650 | 19,430 | - | 2.5 | 11,439 | Common Stock |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 4,650 | 541 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | Stephen B. Shrewsbury | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) |